Achieve Life Sciences: Countdown to Revolution – Is the Greatest Breakthrough in Smoking Cessation in 20 Years on the Horizon?

Current Developments and Upcoming FDA Decision Achieve Life Sciences (ACHV) is approaching one of the most significant phases in its corporate history. At the recent annual meeting of the Society for Research on Nicotine and Tobacco in March 2026, the company presented promising new data on its lead candidate, Cytisiniclin. The results from the Phase 3 analysis, as well as the ORCA-OL long-term study, demonstrate a high efficacy in smoking cessation. Particularly noteworthy is the evidence that the drug was also effective in patients who had...